LARIMAR THERAPEUTICSCS INC

LARIMAR THERAPEUTICSCS INC Share · US5171251003 · LRMR · A2P5PP (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LARIMAR THERAPEUTICSCS INC
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
8
0
0
0
No Price
01.05.2026 23:53
Current Prices from LARIMAR THERAPEUTICSCS INC
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
LRMR
USD
01.05.2026 23:53
3,95 USD
-0,11 USD
-2,71 %
IEXG: IEX
IEX
LRMR
USD
01.05.2026 19:59
3,93 USD
-0,13 USD
-3,20 %
XDUS: Düsseldorf
Düsseldorf
LTIRSD03.DUSB
EUR
30.04.2026 17:30
3,52 EUR
-0,20 EUR
-5,38 %
XDQU: Quotrix
Quotrix
LTIRSD03.DUSD
EUR
30.04.2026 05:27
3,72 EUR
-
Share Float & Liquidity
Free Float 59,78 %
Shares Float 51,16 M
Shares Outstanding 85,58 M
Invested Funds

The following funds have invested in LARIMAR THERAPEUTICSCS INC:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
7,26
Percentage (%)
0,02 %
Company Profile for LARIMAR THERAPEUTICSCS INC Share
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Company Data

Name LARIMAR THERAPEUTICSCS INC
Company Larimar Therapeutics, Inc.
Symbol LRMR
Website https://www.larimartx.com
Primary Exchange XNAS NASDAQ
WKN A2P5PP
ISIN US5171251003
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Carole S. Ben-Maimon
Market Capitalization 337 Mio
Country United States of America
Currency USD
Employees 0,1 T
Address Three Bala Plaza East, 19004 Bala Cynwyd
IPO Date 2014-06-19

Stock Splits

Date Split
29.05.2020 1:12

ID Changes

Date From To
29.05.2020 ZFGN LRMR

Ticker Symbols

Name Symbol
Düsseldorf LTIRSD03.DUSB
Frankfurt ZA71.F
NASDAQ LRMR
Quotrix LTIRSD03.DUSD
More Shares
Investors who hold LARIMAR THERAPEUTICSCS INC also have the following shares in their portfolio:
KINARUS THERAPEUTICS HOLDING AG
KINARUS THERAPEUTICS HOLDING AG Share
WRTS LKD ORDS WUHAN DEPT 11/03/25
WRTS LKD ORDS WUHAN DEPT 11/03/25 Verbriefte Derivate